Abstract
Antimicrobial-resistant Mycoplasma genitalium is becoming increasingly common and creating major treatment challenges. We present early data on combination therapy with doxycycline and sitafloxacin to treat highly resistant M. genitalium. We found the regimen was well tolerated and cured 11/12 infections that had failed prior regimens with moxifloxacin and pristinamycin.
Highlights
Antimicrobial-resistant Mycoplasma genitalium is becoming increasingly common and creating major treatment challenges
Most publications on sitafloxacin are from Japan, where its use as a monotherapy is reported to cure ≈90% of M. genitalium infections [11]
We provide early data on the efficacy and tolerability of a 7-day doxycycline+sitafloxacin combination therapy for treatment-resistant M. genitalium
Summary
Antimicrobial-resistant Mycoplasma genitalium is becoming increasingly common and creating major treatment challenges. Sequential monotherapy with doxycycline followed by moxifloxacin [7,8,9] is currently first-line therapy for macrolide-resistant M. genitalium in guidelines in Australia and the United Kingdom and achieves cure in 92% of cases (95% CI 88.1%–94.6%) at our service [7]. Since August 2017, for patients in whom both regimens failed, we administered a combination of 100 mg doxycycline and 100 mg sitafloxacin 2 times/day for 7 days. We provide early data on the efficacy and tolerability of a 7-day doxycycline+sitafloxacin combination therapy for treatment-resistant M. genitalium.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
